Document Detail


Radioimmunotherapy with anti-CD66 antibody: improving the biodistribution using a physiologically based pharmacokinetic model.
MedLine Citation:
PMID:  20150257     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To improve radioimmunotherapy with anti-CD66 antibody, a physiologically based pharmacokinetic (PBPK) model was developed that was capable of describing the biodistribution and extrapolating between different doses of anti-CD66 antibody. METHODS: The biodistribution of the (111)In-labeled anti-CD66 antibody of 8 patients with acute leukemia was measured. The data were fitted to 2 PBPK models. Model A incorporated effective values for antibody binding, and model B explicitly described mono- and bivalent binding. The best model was selected using the corrected Akaike information criterion. The predictive power of the model was validated comparing simulations and (90)Y-anti-CD66 serum measurements. The amount of antibody (range, 0.1-4 mg) leading to the most favorable therapeutic distribution was determined using simulations. RESULTS: Model B was better supported by the data. The fits of the selected model were good (adjusted R(2) > 0.91), and the estimated parameters were in a physiologically reasonable range. The median deviation of the predicted and measured (90)Y-anti-CD66 serum concentration values and the residence times were 24% (range, 17%-31%) and 9% (range, 1%-64%), respectively. The validated model predicted considerably different biodistributions for dosimetry and therapeutic settings. The smallest (0.1 mg) simulated amount of antibody resulted in the most favorable therapeutic biodistribution. CONCLUSION: The developed model is capable of adequately describing the anti-CD66 antibody biodistribution and accurately predicting the time-activity serum curve of (90)Y-anti-CD66 antibody and the therapeutic serum residence time. Simulations indicate that an improvement of radioimmunotherapy with anti-CD66 antibody is achievable by reducing the amount of administered antibody; for example, the residence time of the red marrow could be increased by a factor of 1.9 +/- 0.3 using 0.27 mg of anti-CD66 antibody.
Authors:
Peter Kletting; Thomas Kull; Donald Bunjes; Bettina Mahren; Markus Luster; Sven N Reske; Gerhard Glatting
Related Documents :
1473827 - Accuracy of drug infusion pumps under computer control.
20540627 - Integration of in silico and in vitro platforms for pharmacokinetic-pharmacodynamic mod...
18452417 - Population pharmacokinetics of cefepime in neonates with severe nosocomial infections.
8563327 - Estimation of pharmacokinetic model parameters.
1473827 - Accuracy of drug infusion pumps under computer control.
12400937 - Optimized contaminated land investigation at minimum overall cost to achieve fitness-fo...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-02-11
Journal Detail:
Title:  Journal of nuclear medicine : official publication, Society of Nuclear Medicine     Volume:  51     ISSN:  1535-5667     ISO Abbreviation:  J. Nucl. Med.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-03     Completed Date:  2010-04-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0217410     Medline TA:  J Nucl Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  484-91     Citation Subset:  IM    
Affiliation:
Klinik f?r Nuklearmedizin, Universit?t Ulm, Ulm, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antibodies / administration & dosage,  immunology*,  metabolism,  therapeutic use*
Antigens, CD / immunology*
Cell Adhesion Molecules / immunology*
Female
Humans
Leukemia / metabolism,  physiopathology,  radiotherapy
Male
Middle Aged
Models, Biological*
Radioimmunotherapy*
Reproducibility of Results
Tissue Distribution
Yttrium Radioisotopes / chemistry
Chemical
Reg. No./Substance:
0/Antibodies; 0/Antigens, CD; 0/CD66 antigens; 0/Cell Adhesion Molecules; 0/Yttrium Radioisotopes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reduction of the ring size of radiolabeled lactam bridge-cyclized alpha-MSH peptide, resulting in en...
Next Document:  Targeted Contrast-Enhanced Ultrasound Imaging of Tumor Angiogenesis with Contrast Microbubbles Conju...